Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
News: $NVRO Here's Why Nevro Stock Bounded Higher on Thursday
Shares of Nevro (NYSE: NVRO) , a medical device company with a focus on pain management, are soaring in response to a positive third-quarter earnings report. The company reported earnings and revenue that blew past analyst expectations, and raised guidance for the rest of 2019. As a...
New system with both lower frequency ranges and combination therapies, in addition to HF10 (10k Hz) ranges, and brand new patient peripherals (ie, remote, charger, etc) should be out in November I’m told.
News: $NVRO Nevro to Highlight Substantial Body of Clinical Evidence Supporting Expanded Applications and Unique Capabilities of HF10 Therapy at the 14th International Neuromodulation Society World Congress
SYDNEY , May 26, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced a series of data presentations supporting the use of the Company's HF10Ȓ...
Today Nevro submitted and posted a link to their preliminary response to the patent trial and appeals board with reference to the Boston Scientific Corporation challenge to the key Nevro patent. See http://www.nevro.com/press-release/?r=US&prid=5aa76c3f-164d-4b00-8def-f9ad36ba33b2. I personally, though not a lawyer, was impressed by the strength of the rebuttal. On another note, I have heard that the first few patients in my state that have received the preliminary trial for effectiveness of the Senza have faired well, and are going to move on to permanent implants. A number of advisory services have not been favorably viewing Nevro, but IMO that is because they are looking at past performance and not considering the game change that FDA approval represents. Others that look at the whole picture, such as Zacks, are very high on NVRO (Rank 1). Long on NVRO, and added on the recent dip. The sparseness of contributions to this board is an indication that the stock is flying under the radar. I was clued in when the Senza was recommended for my spouse.
Nevro Corp. is a medical device company focused on developing solutions in the neuromodulation space. The Company provides pain relief to the customers suffering from low back pain and types of chronic pains. The Company’s High-frequency spinal cord stimulation (SCS) system, the HF10 SCS, is a spinal cord simulation therapy, which provides electric pulses at a rate of approximately 10,000 Hz for spinal cord stimulation in the treatment of chronic back and leg pain. The electrical pulses are conveyed by small electrodes placed in the epidural space and connected to a battery-powered generator implanted under the skin. The Nevro Senza SCS system is available in Europe and Australia. It is undergoing a pivotal clinical trial, which is intended to collect data to support an application for a Nevro Senza implantable spinal cord stimulation system. The Company’s SENZA-RCT study is intended to evaluate the safety and effectiveness of the Senza SCS system.
Nevro Corp. is a medical device company focused on developing solutions in the neuromodulation space. The Company provides pain relief to the customers suffering from low back pain and types of chronic pains. The Company’s High-frequency spinal cord stimulation (SCS) system, the HF10 SCS, is a spinal cord simulation therapy, which provides electric pulses at a rate of approximately 10,000 Hz for spinal cord stimulation in the treatment of chronic back and leg pain. The electrical pulses are conveyed by small electrodes placed in the epidural space and connected to a battery-powered generator implanted under the skin. The Nevro Senza SCS system is available in Europe and Australia. It is undergoing a pivotal clinical trial, which is intended to collect data to support an application for a Nevro Senza implantable spinal cord stimulation system. The Company’s SENZA-RCT study is intended to evaluate the safety and effectiveness of the Senza SCS system.
https://www.google.com/finance?q=NVRO